What else gets tracked

The liver carries two roles at once in this picture, and they mix easily. In the first it’s a source: the release pushing up the morning reading starts there. In the second it’s a target. Fat fills in among its own cells, the tissue stiffens in time, and the organ moves to the result side, not the cause. “What is the link between weight and diabetes?” sees the same organ from the cause side.

In most people the built-up fat stays put. The reference text compiling liver diseases calls plain fatty buildup a picture that can reverse and doesn’t progress; progression shows up in the part where inflammation is added on top. There the tissue stiffens, and the picture at the far end of the stiffening is called cirrhosis. The picture has no way of announcing itself either: most patients feel nothing. Its name on the paper changed recently. The old name was fatty liver disease; today it goes by a name putting the metabolic origin up front.

The prevalence number is read on this ground. The American Diabetes Association’s consensus report writes that roughly two in three people living with type 2 diabetes have fat in the liver. The same report also names a gap outright: liver health has never entered the front row of followed complications like eye, kidney and nerve. The liver carries its own line on the medication side too: “How many groups do diabetes medications fall into?” splits groups by the organ they touch.

All four measures go quiet somewhere different. The paper’s enzyme line isn’t enough alone: the same reference text writes that mildly raised enzymes are the most common finding, yet in most patients they run normal. A normal line doesn’t clear the organ. Indexes figured from blood were developed for this gap; the most reachable is called FIB-4, wants no new test, and is figured from numbers already on the paper. Its power gathers at the ends: direction sharpens at the low and high end, accuracy drops in the middle band, even more so at older ages and in type 2 diabetes. In the method that measures stiffness from outside, the reading loses reliability as body measurements grow. The tissue sample is the method that settles the diagnosis, kept for cases whose result stays uncertain.

What’s left: the two measures don’t answer the same question from the same place. The enzyme line reports the cell’s state that day. The index doesn’t read the same line alone; it counts it alongside age and another number in the blood panel. So the index can rise while the enzyme line looks ordinary. On the liver side these two lines are read separately.

Sugar doesn’t act alone in this picture. Two more burdens stand beside it, and all three end up in the same place: the vessel wall. Blood pressure pushes the vessel from inside; blood fats settle into the wall itself. Diabetes makes both jobs easier.

Picturing pressure as a bicycle tire helps. A tire setting out at high pressure wears at its thinnest point. That thin point in the body is the kidney’s filter units and the capillary web behind the eye. Wear eases on both sides when pressure drops, measured in a broad review pooling forty studies.

Blood fats work another way. Particles slipping under the vessel lining collect there and build plaque; the heart article covers the process itself. This side concerns the heart, brain, and leg circulation. Cholesterol-lowering treatments were found to cut vascular events at the same rate in people with diabetes as in those without.

The three share one more trait: none makes itself felt. Neither high pressure nor high blood fats has a daily symptom; both show in an arm reading and a blood test. Narrowing vessels’ best-known sign is in the legs: your calf seizing as you walk back from the store, easing when you stop and wait.

Handling them separately is one thing, together another. A study in a group leaking albumin into the urine tested just that. Targeting glucose, pressure, and blood fats at once left vascular events and the death rate clearly lower than care focused on one burden. In the long years since, the gap didn’t close.

Giving numbers has no point, since targets are built person by person. What matters is this: a lab result’s lines aren’t independent. If the sugar line improves while blood pressure and blood fats stay put, two-thirds of the vessel-side load still sits in place.

The list doesn’t end there: smoking, and how the kidney works. The kidney isn’t only a target organ; it’s also a measure. When filtering slows, many medications stay in the body longer, managing blood pressure gets harder, and treatment choice shifts accordingly. So the filtering rate sits beside the blood pressure line.

For you, this comes down to something simple. Why diabetes monitoring isn’t only measuring sugar is answered here; the blood pressure cuff and the blood fat line weren’t added to the list for show. But the main burdens are these three.